Empty Rhetoric: Novo Nordisk’s Sales Rise 364%
“We are opposed to plans where the financial interest of the manufacturer takes precedence over the patient's health. To call a physician and say that we're changing a patient's medication and make it seem as if it's on behalf of the patient when it's actually part of this marketing deal is not right.”
Carmen Catizone, executive director, National Association of Boards of Pharmacy.
Gardiner Harris, Robert Pear, “Drug Maker’s Efforts to Compete in Lucrative Insulin Market Are Under Scrutiny,” New York Times,
Comments on "Empty Rhetoric: Novo Nordisk’s Sales Rise 364%"
post a comment